Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Elevated inflammation common in children’s severe COVID-19 disease

Key clinical point: Comorbidities were common among children and young adults with severe COVID-19 disease; more severe cases showed elevated inflammatory markers.

Major finding: Patients with severe disease had significantly higher levels of C-reactive protein, procalcitonin, peak interleukin 6, ferritin, and D-dimer, compared with those with less severe disease

Study details: The data come from a retrospective study of 50 children and young adults aged 21 years and younger who tested positive for COVID-19 between March 1 and April 15, 2020.

Disclosures: The study received no outside funding. Dr. Zachariah had no financial conflicts to disclose. Two coauthors reported ties with various pharmaceutical companies and organizations.